Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 13,564 | 16,174 | 11,351 | 13,032 | 7,485 |
| Cost of Goods | 1,525 | 1,589 | 1,244 | 1,427 | 897 |
| Gross Profit | 12,039 | 14,585 | 10,107 | 11,605 | 6,588 |
| Operating Expenses | 34,521 | 35,089 | 33,791 | 34,855 | 33,599 |
| Operating Income | -21,957 | -19,915 | -23,440 | -22,823 | -26,114 |
| Interest Expense | 282 | 0 | 0 | 0 | 0 |
| Other Income | -5,828 | -7,400 | -6,771 | -3,087 | 179 |
| Pre-tax Income | -28,067 | -27,315 | -30,211 | -25,910 | -25,935 |
| Income Tax | 325 | 1,137 | N/A | 312 | N/A |
| Net Income Continuous | -28,392 | -28,452 | -30,211 | -26,222 | -25,935 |
| Net Income | $-28,392 | $-28,452 | $-30,211 | $-26,222 | $-25,935 |
| EPS Basic Total Ops | -1.25 | -1.27 | -1.35 | -1.17 | -1.17 |
| EPS Basic Continuous Ops | -1.25 | -1.27 | -1.35 | -1.17 | -1.17 |
| EPS Diluted Total Ops | -1.25 | -1.27 | -1.35 | -1.17 | -1.17 |
| EPS Diluted Continuous Ops | -1.25 | -1.27 | -1.35 | -1.17 | -1.17 |
| EBITDA(a) | $-21,692 | $-19,569 | $-23,061 | $-22,623 | $-25,732 |